A Gene Hunting Study for Familial Papillary Thyroid Cancer

Thyroid Clinical Trial

Official title:

A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02776969
• Other study ID #: OSU-9812
• Status: Recruiting
• Start date: August 5, 1998
• Est. completion date: December 2023

Study information

• Verified date: October 2022
• Source: Ohio State University Comprehensive Cancer Center
• Contact: Ohio State University Comprehensive Cancer Center
• Phone: 614-293-5066
• Email: OSUCCCClinicaltrials[@]osumc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.

Description:

The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). This can be accomplished in several ways, including loss of heterozygosity studies as well as comparative gene expression analysis. When possible, linkage analysis on families with multiple individuals affected with PTC may also help identify the putative gene(s). Study participants will be asked to: 1. Complete family history and medical history questionnaires 2. Sign a medical record release so that thyroid cancer pathology reports can be obtained 3. Supply a blood or saliva sample for genetic studies 4. Provide study related information to family members who are needed for family studies

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1200
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of PTC and a family history of PTC in 3 or more living relatives
• Affected and unaffected family members of the proband*
• For familial cases (families with 4 or more cases of PTC), participation will be offered to all living family members with PTC or benign thyroid disease as well as selected unaffected first and second degree relatives. Participation may also be offered to spouses when needed for analyzing parent/offspring samples.

Exclusion Criteria:

• Known germline predisposition (ex: pathogenic PTEN variant)
• Non-English speaking

Related Conditions & MeSH terms

• Thyroid
• Thyroid Diseases

Locations

Country	Name	City	State
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetic variants associated with familial papillary thyroid cancer as assessed by multiple genetic testing methodologies	Variants will be assessed for segregation within families, expression in the normal thyroid and/or thyroid cancer, and functional significance	Up to 5 years

External Links

•   The Jamesline